During the last session, Tourmaline Bio Inc (NASDAQ:TRML)’s traded shares were 0.7 million, with the beta value of the company hitting 2.34. At the end of the trading day, the stock’s price was $23.02, reflecting an intraday gain of 1.86% or $0.42. The 52-week high for the TRML share is $48.31, that puts it down -109.86 from that peak though still a striking 60.12% gain since the share price plummeted to a 52-week low of $9.18. The company’s market capitalization is $590.23M, and the average intraday trading volume over the past 10 days was 0.19 million shares, and the average trade volume was 229.91K shares over the past three months.
Tourmaline Bio Inc (NASDAQ:TRML) trade information
Tourmaline Bio Inc (TRML) registered a 1.86% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.86% in intraday trading to $23.02, hitting a weekly high. The stock’s 5-day price performance is 19.46%, and it has moved by 58.10% in 30 days. Based on these gigs, the overall price performance for the year is -19.51%. The short interest in Tourmaline Bio Inc (NASDAQ:TRML) is 2.14 million shares and it means that shorts have 17.0 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target of analysts on Wall Street is $72, which implies an increase of 68.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $50 and $74 respectively. As a result, TRML is trading at a discount of -221.46% off the target high and -117.2% off the low.
Tourmaline Bio Inc (TRML) estimates and forecasts
Statistics show that Tourmaline Bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Tourmaline Bio Inc (TRML) shares have gone down -19.54% during the last six months, with a year-to-date growth rate more than the industry average at 64.83% against 20.70. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 84.80% this quarter and then drop -9.90% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -19.23%. While earnings are projected to return 65.56% in 2024.
TRML Dividends
Tourmaline Bio Inc is due to release its next quarterly earnings on 2024-Nov-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
